Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Hematology
•
Diabetes
•
Endocrinology
Do you routinely monitor INR when starting GLP1 R agonist therapy on patients taking warfarin?
Related Questions
Do you recommend early oral nutrition when managing diabetic ketoacidosis?
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
Under what circumstances would you test for hypercortisolism in a patient with insulin resistance?
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
How would you counsel a female to male transgender patient regarding VTE risk with testosterone therapy, who has additional mild-moderate risk factors for thrombosis?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
